SUBSCRIBE
SUBSCRIBE

Mark Zipkin

Drug Development
Actemra Reduces Deaths, Mechanical Ventilation for COVID-19 in Early Data
Early results from University of Oxford’s RECOVERY trial showed Roche’s immunosuppressant Actemra reduced deaths and the need for mechanical ventilation in severe COVID patients.
February 12, 2021
 · 
2 min read
 · 
Mark Zipkin
Business
Ensoma Launches with $70 Million Series A and Takeda Licensing Deal
As part of the Takeda deal, Ensoma will do preclinical research for therapies in up to five rare disease indications, and both companies will work on Investigational New Drug-enabling studies.
February 11, 2021
 · 
2 min read
 · 
Mark Zipkin
Kate Krav-Rude/Shutterstock
Business
AbbVie, Caribou Biosciences Collaborate in $40 Million CAR-T Cell Deal
AbbVie committed up to another $300 in potential milestone payments.
February 10, 2021
 · 
2 min read
 · 
Mark Zipkin
Business
Notch Soars Out of the Gate with $85 Million; Two More Follow Closely Behind
There have been a few life sciences companies that have been attracting attention this week with strong Series A rounds.
February 10, 2021
 · 
2 min read
 · 
Mark Zipkin
Jeremy Moeller/Getty Images
Lonza to Sell Specialty Ingredients Division for $4.7 Billion, Pivot to Pharma
Lonza has been in the process of separating LSI into a standalone unit since 2019.
February 9, 2021
 · 
2 min read
 · 
Mark Zipkin
Deals
Bolt, Vor IPO Pricings Top $400 Million Cap Huge Week for Life Science Financing
Innate immune-oncology company Bolt expects to raise $230 million, and cancer cell therapy player Vor Biopharma expects to raise $176.9 million, in upsized initial public offerings (IPOs) starting today, following yesterday’s $587.5 million IPO for Sana Biotechnology and other financing news this week.
February 5, 2021
 · 
2 min read
 · 
Mark Zipkin
FDA Recalls Catheter, Cardiac Devices and Meds Over Safety Issues
From packaging errors and contaminants to serious adverse effects, there are many reasons why products in the life sciences industry get recalled. Here’s a look at some of the latest drug and medical device recalls.
February 4, 2021
 · 
3 min read
 · 
Mark Zipkin
Drug Development
Phase III Updates: CanSino, Global Blood Therapeutics, Travere and NeurMedix
A few companies shared some big Phase III results this week. Here’s a look.
February 3, 2021
 · 
2 min read
 · 
Mark Zipkin
Michael Vi/Shutterstock
Deals
Jazz Moves to Snap Up Cannabinoid Company, Bolster Neurology Pipeline
Jazz Pharmaceuticals will beef up its neurology pipeline with a $7.2 billion buyout of GW Pharmaceuticals, the only company yet to score U.S. regulatory approval for a cannabis-derived product.
February 3, 2021
 · 
2 min read
 · 
Mark Zipkin
grandbrothers/Shutterstock
Policy
FDA to Require Additional Study for Eagle’s Generic Vasopressin
Eagle Pharmaceuticals is still struggling to get its generic vasopressin to market, announcing both a regulatory stall and an additional trial delay for a patent case with Endo Par Innovation Company over the drug.
February 2, 2021
 · 
1 min read
 · 
Mark Zipkin
Genetown
Cellino Raises $16 Million Seed Round for AI-Guided Cell Therapies
The round was led by The Engine, a venture capital firm born at Massachusetts Institute of Technology, and Khosla Ventures and joined by Humboldt Fund and 8VC.
February 1, 2021
 · 
2 min read
 · 
Mark Zipkin
Sundry Photography / GettyImages
Drug Development
New Amivantamab Data Bolsters Janssen’s Hopes for Approval in NSCLC Subpopulation
Janssen presented additional positive data from its phase I study of its bispecific antibody amivantamab in metastatic or unresectable non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations.
January 29, 2021
 · 
2 min read
 · 
Mark Zipkin
Ji Haixin/VCG via Getty Images
Drug Development
BeiGene’s Tislelizumab Improves Survival in Esophageal Cancer Study
BeiGene continues its roll with anti-PD-1 monoclonal antibody tislelizumab, announcing topline data yesterday from its fourth positive Phase III trial, this time in esophageal squamous cell carcinoma.
January 28, 2021
 · 
2 min read
 · 
Mark Zipkin
Rezafungin showed good results in Phase III trials
Drug Development
More Positive Data Sets Up Agios’ Mitapivat for Regulatory Filings This Year
Agios reported its second positive Phase III readout for small molecule mitapivat to treat pyruvate kinase deficiency, this time meeting its primary endpoint of reduced blood transmission burden.
January 27, 2021
 · 
2 min read
 · 
Mark Zipkin
Courtesy of Getty Images
Drug Development
Data Shows Eli Lilly Antibody Combo Cuts COVID-19 Hospitalizations, Deaths
New Phase III efficacy data from Eli Lilly showed that a combination of two experimental neutralizing antibodies, bamlanivimab and etesevimab, met the primary endpoint of reduced hospitalizations and deaths from COVID-19.
January 26, 2021
 · 
2 min read
 · 
Mark Zipkin
Load More